hydroxychloroquine - for COVID-19 prophylaxis method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.70 [0.24, 2.05]< 10%2 studies (2 / -)74.4 %some concernnot evaluable moderatecrucial-
conversion to SARS-CoV- 2–positive status via NP swab 1.57 [0.93, 2.64]< 10%4 studies (4 / -)4.6 %some concernnot evaluable moderateimportant-
hospitalization 0.98 [0.06, 15.77]< 10%1 study (1 / -)50.5 %lownot evaluable highimportant-
new illness compatible with Covid-19 0.80 [0.63, 1.01]< 10%4 studies (4 / -)97.1 %some concernnot evaluable moderateimportant-
PCR-confirmed, symptomatic Covid-19 disease 0.90 [0.60, 1.36]< 10%4 studies (4 / -)69.0 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 89 89